Equities

Carisma Therapeutics Inc

Carisma Therapeutics Inc

Actions
  • Price (EUR)0.943
  • Today's Change-0.019 / -1.98%
  • Shares traded470.00
  • 1 Year change-68.77%
  • Beta--
Data delayed at least 15 minutes, as of Nov 08 2024 14:51 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments78167163
Total Receivables, Net--0.8324
Total Inventory------
Prepaid expenses2.870.4018
Other current assets, total--210
Total current assets80189206
Property, plant & equipment, net8.9400.04
Goodwill, net--013
Intangibles, net--015
Long term investments------
Note receivable - long term------
Other long term assets--00.12
Total assets90189241
LIABILITIES
Accounts payable3.931.232.85
Accrued expenses8.99298.37
Notes payable/short-term debt000
Current portion long-term debt/capital leases0.54----
Other current liabilities, total2.440.350.35
Total current liabilities163112
Total long term debt0.3300
Total debt0.8700
Deferred income tax--03.97
Minority interest0----
Other liabilities, total47054
Total liabilities633169
SHAREHOLDERS EQUITY
Common stock0.040.200.20
Additional paid-in capital272495488
Retained earnings (accumulated deficit)(245)(336)(316)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total0(0.55)--
Total equity27158172
Total liabilities & shareholders' equity90189241
Total common shares outstanding41109.97
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.